Eli Lilly’s lepodisiran slashes inherited heart disease risk factor by 94% in Phase 2 trial
Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on ...
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...
Devdiscourse2h
WHO Job Cuts and Groundbreaking Lilly Drug Trial: Health News Highlights
The WHO plans to reduce its workforce and budget by over 20% due to reduced U.S. funding, according to an internal memo. Meanwhile, an Eli Lilly trial showed their experimental drug lepodisiran cut a ...
BioSpace3h
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...
Medical Marketing & Media3d
DTC platform LillyDirect expands to provide access for Alzheimer’s care
Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...